Figure 2From: A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma Kaplan-Meier Analysis of Overall Survival and Progression Free Survival. Among 40 patients, the median overall survival was 358 days (11.7 months) and the progression free survival was 57 days (1.9 months).Back to article page